Levetiracetam (LEV) is a new antiepileptic drug (AED) indicated as adjunctive therapy in the treatment of partial seizures and primary generalized seizures. Both initial clinical trials and post-release clinical experience [1] [2] [3] show that previously drug resistant epileptic patients may be rendered seizure free with add-on therapy with LEV. In two recent studies examining LEV efficacy on drug resistant patients in everyday clinical practice, 16.3% and 10% respectively achieved seizure freedom after addition of LEV therapy 4, 5 . Recent studies suggest LEV efficacy also as monotherapy in new-onset partial epilepsy and idiopathic generalized epilepsy 6, 7 . Because of its favorable pharmacokinetic profile, LEV is particularly suitable for special populations (such as elderly patients, patients with cognitive problems, patients with treated co-morbidities) in which traditional AEDs are often poorly tolerated because of drug-todrug interactions, negative impact on cognitive function, toxicity on liver function 8, 9 .
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ABSTRACT: Background: The aim of this study was to evaluate efficacy and tolerability of levetiracetam (LEV) in patients with different epilepsy syndromes. Methods: We evaluated epileptic patients seen in the previous 18 months, including all patients with present or past exposure to LEV. Tolerability of LEV therapy was evaluated in all patients; efficacy was evaluated only in patients who had received LEV for at least six months. Two hundred and two patients were included in the study. Patients were considered responsive when showing a > 50% reduction in seizures frequency and non-responders when seizure frequency was unchanged, worsened or showed a reduction < 50%. Results: Thirty patients did not complete six months of LEV treatment and dropped out. 57.4% of the patients with uncontrolled seizures treated for at least six months were responders, with 27.7% seizure free. Adverse effects were observed in 46 patients (23%) and were responsible for early drop out in 26. Adverse effects occurred significantly more often in females than in males (30.6% vs 13.2%); moreover, nearly 30% of women with adverse effects complained of more than one adverse effect, while this was never observed in male patients. Conclusions: Our study shows LEV as a well tolerated and effective treatment, both in monotherapy and as an add-on. Further investigations on larges samples are needed to investigate the issue of gender-related tolerability.
patients, while efficacy of LEV treatment was evaluated only in patients who had received LEV for at least six months after titration. Demographic and clinical data were evaluated retrospectively from clinical charts; seizure frequency was evaluated from patients' diaries, a tool that all our patients in our service are instructed to employ. Patients and/or caregivers note every seizure in a diary, indicating clinical features and, when present, precipitating factors. The examining doctor collects this information at every appointment and writes it down in the patient's chart. For the purpose of this study, seizure frequency in the six months preceding LEV treatment was considered as baseline; for patients with newly diagnosed epilepsy, baseline was obtained by dividing the total number of seizures presented since the onset of epilepsy by the months of epilepsy duration at study entry. All patients with newly diagnosed epilepsy included in this study had epilepsy duration of at least four months at study entry. Material: Two hundred-two patients met the inclusion criteria and were included in the study (Table 1) . Ninety-one were males and 111 females, ranging in age from 7 to 93 yrs. One hundred forty-six patients were affected by focal epilepsies and 56 by generalized epilepsies; in particular 48 patients were affected by Idiopathic Generalized Epilepsy (IGE), 8 patients by Symptomatic Generalized Epilepsy (SGE), 2 patients by Idiopathic Focal Epilepsy (IFE), 57 by Cryptogenic Focal Epilepsy (CFE) and 87 by Symptomatic Focal Epilepsy (SFE). Thirty of these 202 patients (14.8%) dropped out of the study before completing six months of LEV treatment, because of adverse effects in 26 and worsening of seizures in 4. Consequently, efficacy of LEV treatment was evaluated only in 172 patients treated with LEV for at least six months, which for the purpose of analysis were subdivided in three groups:
Controlled Seizures Group: These 31 patients had already achieved complete seizure control with previous AED therapy but reported adverse effects related to treatment; in these subjects LEV was introduced with the aim of reducing or withdrawing previous AED treatment. De Novo Group: These 19 patients had newly diagnosed epilepsy which had never been treated; LEV was used as first line drug because of its favorable profile. Drug Resistant Group: These 122 patients had drug resistant seizures and received LEV with the aim of improving seizure control.
Patients were considered responsive when showing relevant improvement with LEV treatment; in particular, they were considered seizure free when achieved seizure freedom and responders when they showed a > 50% but < 100% reduction in seizures frequency. Patients were considered non-responders when seizure frequency was unchanged, worsened or showed a reduction of ≤ 50%. Response to LEV therapy was evaluated separately in Controlled Seizures, De Novo and Drug Resistant Groups. Moreover, in the Drug Resistant Group response to therapy was evaluated separately according to epilepsy type.
Statistical analysis: Statistical analysis was performed by Dianthus Medical using STATA version 11. Both tolerability and efficacy were analyzed by logistic regression, performing univariate and multivariate analyses. For tolerability, the presence of adverse effects was considered as the outcome, and univariate logistic regression analysis was performed for the following variables: age, sex, epilepsy type (focal or generalized), LEV monotherapy, number of concomitant AEDs, LEV daily dose, LEV plasma levels. Two multivariate logistic regression analyses were performed in the analysis of tolerability, the first including only age, sex and LEV daily dose, and the second including all predictor variables except for LEV plasma levels which had many missing values. Statistical analysis of efficacy was performed only in the Drug Resistant Group which was the most numerous, while the others two were quite small. Since efficacy had three possible outcomes (non- responder, responder, seizure-free), ordinal logistic regression was performed. In particular, univariate logistic regression analysis was performed for the following variables: age, sex, epilepsy type (focal or generalized), LEV monotherapy, presence of abnormal magnetic resonance imaging (MRI) findings, history of surgery for epilepsy or being candidate to surgery for epilepsy, history of status epilepticus, adverse effects to LEV, number of concomitant AEDs, LEV daily dose, LEV plasma levels. In order to fully examine the relationships among possible outcomes and predictor variables, several multivariate analyses were performed: the first included only age, sex and LEV daily dose; the second included age, sex and all significant univariate predictors except LEV plasma levels; the third included age, sex and all significant univariate predictors except LEV plasma levels, LEV daily dose and number of concomitant drugs; the fourth included all predictors except LEV plasma levels; the fifth included all predictors except LEV plasma levels, LEV daily dose and number of concomitant drugs. P < 0.05 was considered significant.
RESULTS

Tolerability
Adverse effects were observed in 46 patients out of 202 patients (23%) and led to LEV withdrawal in 32 (16%); 26 of these 32 patients dropped out before completing six months of LEV treatment. Several patients (pts) complained of more than one adverse effect: the most frequent complaints were drowsiness (16 pts), irritability (9 pts), asthenia (8 pts), gastric discomfort (5 pts). More rarely, patients complained of insomnia (2 pts), skin rash (2 pts), depression (2 pts), headache (2 pts), severe behavioral disturbances (2 pts reported by one patient each, were diarrhea, vomiting, weightloss, dizziness, memory disturbances, tremor, pruritus and visual disturbances. Statistical analysis (Table 2) showed no significant association of adverse effects with age groups, epilepsy type (focal or generalized), percentage of monotherapy patients, number of concomitant AEDs. There was a significant association with sex, in particular with adverse effects associated with female patients. In particular, adverse effects were reported in 34 out of 111 female patients (30.63%) and in 12 out of 91 male patients (13.19%). Moreover, adverse effects were significantly associated with low daily doses of LEV and with low LEV plasma levels. It must be underlined that LEV plasma levels were obtained only in 123 patients out of 202.
Efficacy
Results of the efficacy study are summarized in Table 3 . The 31 patients of the Controlled Seizures Group were already seizure free and received LEV in order to reduce or withdraw previous AED treatment, responsible of adverse effects (impaired libido, menstrual disturbances, tremor, liver function impairment, dizziness, behavioral disturbances, mood changes, cognitive impairment, etc.). Most of these patients (20 out of 31) were affected by focal epilepsies with complex partial seizures and/or simple partial seizures, occasionally with secondary generalization. The remaining 11 had generalized epilepsies with absences and/or myoclonic seizures and/or tonic-clonic generalized seizures. Twenty-two of these 31 patients (71.0%) were switched to LEV monotherapy while in the remaining nine LEV was given as add-on treatment with reduction of concomitant AEDs. After this therapy change, 30/31 patients (96.8%) preserved seizure freedom, while one patient with focal epilepsy, who had been switched from Phenobarbital to LEV, had a recurrence of seizures (a single focal seizure with secondary generalization). In all patients of this group the withdrawal or reduction of previous AED therapy was accompanied by improvement or disappearance of previously reported adverse effects. However, four patients in this group reported new side effects (irritability in two, drowsiness in two) after treatment with LEV. In three of these patients (two on LEV monotherapy, one on LEV add-on to carbamazepine and phenobarbital) the new side effects were transient and disappeared spontaneously or after reduction of LEV oral doses, and did not lead to LEV withdrawal. The remaining patient reported persistent side effects (irritability) on LEV monotherapy: this problem, however, was better tolerated than previous adverse effects (dizziness on carbamazepine treatment) and did not lead to LEV withdrawal.
The 19 patients of the De Novo Group had never been treated with AEDs and LEV monotherapy was introduced as the firstline drug because of its favorable profile. Thirteen patients in this group had focal epilepsies while the remaining had generalized epilepsies. There were 17 patients out of 19 (89.5%) in this group that were responsive to LEV, in particular with 11 seizure-free (57.9%). One of the responding patients reported adverse effects (irritability) which did not lead to drop out from LEV treatment. The two patients (10.5%) who did not respond to LEV were switched to different AEDs after six months of LEV monotherapy. In both of them seizures persisted on a polytherapy regimen.
The 122 patients of the Drug Resistant Group had longstanding drug resistant seizures which had failed to respond to at least two other prior AEDs appropriate for their epilepsy classification. Twelve of them had been gradually switched to LEV monotherapy from previous treatment, while the remaining 110 received LEV as add-on therapy. Sixty-four patients (52.5%) in the Drug Resistant Group were responsive to LEV, with 28 seizure-free (23.0%). Statistical analysis (Table 4) showed that a good outcome was significantly associated with LEV monotherapy, low LEV daily doses, fewer concomitant AEDs, and reversely associated with presence of abnormal MRI findings, history of surgery (or indication for surgery) for epilepsy, history of status epilepticus. No significant association with sex, age and epilepsy type were observed.
The Drug Resistant Group included 26 patients with IGE, 6 with SGE, 1 with IFE, 32 with CFE and 57 with SPE. Idiopathic generalized epilepsy patients showed the best response with 69.2% responsive patients (42.3% seizure-free), while in CFE 53.1% were responsive to LEV (25.0% seizure-free) and in SFE 47.4% were responsive to LEV (14.0% seizure-free). These differences, however, were not significant (Figure) . The groups Non-Responders: patients in whom seizure frequency was unchanged, worsened or showed a reduction ≤ 50% after LEV was introduced; Responders: patients in whom seizure frequency showed a reduction > 50%, but were not seizure-free, after LEV was introduced; Seizure free: patients who became seizure-free (De Novo Group and Drug Resistant Group) or preserved seizure freedom (Controlled Seizures Group) after LEV was introduced. 
Controlled Seizures Group (31 patients)
CONCLUSIONS
The aim of our study was to evaluate, retrospectively, efficacy and tolerability of LEV in patients who had received this drug in the setting of a clinical practice and had not been selected according to a specific study protocol. For this reason, our patient population was quite heterogeneous. Other limitations of our study were the retrospective evaluation of patients and the lack of LEV plasma levels in several patients, which did not allow a satisfactory evaluation and accurate conclusions on this specific issue.
While tolerability was evaluated in the group as a whole, subdivision in different groups allowed an evaluation of efficacy specifically oriented to different clinical features of patients.
In the first group (Controlled Seizures Group), whose patients were already seizure-free, the goal was to maintain seizure freedom while reducing or abating adverse effects related to previous AED treatment.
Because of its favorable pharmacokinetics and good tolerability, LEV is often employed as alternative treatment in patients whose seizures are already controlled with other AEDS, but in whom adverse effects related to treatment have a significant impact on quality of life. In our study, preservation of seizure freedom in these patients was observed in 96.8%, disappearance or relevant reduction of previous adverse effects in 100%, and onset of persistent, but well tolerated LEV-related adverse effects in 3.2%.
The second group (De Novo Group) included patients who had never been treated with AEDS. In newly diagnosed patients the choice of LEV as first-line treatment is usually suggested in special populations such as elderly patients, liver impaired subjects or patients submitted to poly-treatment for co-morbidity. However, due to its efficacy on different kinds of seizures together with good tolerability and favorable pharmacokinetic profile, LEV is gradually becoming a first-choice option in wider populations of epileptic patients. In our study, 89.5% of newly diagnosed patients were responsive to LEV monotherapy, with 57.9% seizure-free.
The third group included patients with uncontrolled seizures (Drug Resistant Group). Drug Resistant patients are a population who present with a history of poor response to AED treatment and usually receive at least two different AEDs. In these subjects, LEV is usually employed as add-on treatment with the aim of controlling seizures; only successively, if seizure control is achieved, concomitant AEDs are reduced in number and dosage, and finally a switch to monotherapy is attempted. In our population of Drug Resistant subjects, 52.5% were responsive to LEV, with 23.0% achieving seizure freedom. Predictably, best results were observed in idiopathic epilepsies. As reported in other studies on refractory seizures 4 , patients who responded best • Statistically significant tended to do so at relatively low doses; good outcomes were predictably associated with fewer concomitant AEDs and more frequent switch to monotherapy. Our study did not allow identification of a specific profile of Drug Resistant patients who could be predicted to be responsive to LEV. The only potentially useful suggestion is that "markers" of severe epilepsy (MRI abnormal findings, history of status, past or programmed surgery for epilepsy) are quite obviously associated with a poor outcome. Outcome does not significantly change in relation to sex, age or epilepsy type (if focal or generalized), and while Idiopathic Epilepsies tend to show a better response than Cryptogenic and Symptomatic forms, the difference among the groups is not significant. Tolerability to LEV was evaluated in the whole group of 202 patients. Adverse reactions to LEV were significantly associated with low oral doses and low plasma levels, suggesting that patients likely to develop adverse effects tend to show them quite early during LEV treatment and that adverse effects are not related to high dosages. There was no significant association of adverse effects with polytherapy, suggesting that impaired tolerance to LEV might not be related to interactions with concomitant AEDs.
Finally, there was a significant predominance of female patients in the group of subjects with adverse effects: this finding, which might suggest a difference in tolerability related to gender, is at the moment quite difficult to interpret. So far, studies investigating tolerability of LEV have not shown differences relating to gender 10, 11 . In our sample, no specific side effect was represented more in the female group, suggesting a global reduction of tolerability in women rather than a particular susceptibility to a specific adverse effect; this was also suggested by the fact that nearly 30% of women with adverse effects complained of more than one adverse effect, while this was never observed in male patients. Drop outs due to adverse effects were observed more often in women, but not significantly. There was no significant difference between males and females with regard to age, co-treatment and epilepsy type; within the female group adverse effects were equally distributed according to age, suggesting that impaired tolerability in these women was not related to a specific period of reproductive age. Further investigations in larger samples are warranted to confirm this interesting finding.
